ADENOVIRUS IL-12 AND DOCETAXEL IN COMBINATION WITH ANTI-PD1 AS AN EFFECTIVE TREATMENT STRATEGY FOR TNBC

被引：0
|
作者：
Qian, Wei [1 ]
Zhou, Jianying [1 ]
Rosato, Roberto [1 ]
Chang, Jenny [1 ]
Anselme, Ann [1 ]
机构：
[1] Houston Methodist Res Inst, Houston, TX USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0437
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
437
引用
收藏
页码：A266 / A266
页数：1
相关论文
共 50 条
  • [31] Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands
    van der Kooij, M. K.
    Joosse, A.
    Speetjens, F. M.
    Hospers, G. A. P.
    Bisschop, C.
    de Groot, J. W. B.
    Koornstra, R.
    Blank, C. U.
    Kapiteijn, E.
    ACTA ONCOLOGICA, 2017, 56 (01) : 101 - 103
  • [32] Anti-PD1 antibody: a new approach to treatment of lymphomas
    Bachy, Emmanuel
    Coiffier, Bertrand
    LANCET ONCOLOGY, 2014, 15 (01): : 7 - 8
  • [33] A novel oncolytic HSV co-expressing IL-12 and anti-PD-1 for glioblastoma
    Ayele, Kalkidan
    Feng, Xiaodong
    Saha, Dipongkor
    MOLECULAR THERAPY ONCOLOGY, 2024, 32 (02):
  • [34] Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF
    Zhang, Song-Nan
    Choi, Il-Kyu
    Huang, Jing-Hua
    Yoo, Ji-Young
    Choi, Kyung-Ju
    Yun, Chae-Ok
    CANCER RESEARCH, 2012, 72
  • [35] Optimizing DC Vaccination by Combination With Oncolytic Adenovirus Coexpressing IL-12 and GM-CSF
    Zhang, Song-Nan
    Choi, Il-Kyu
    Huang, Jing-Hua
    Yoo, Ji-Young
    Choi, Kyung-Ju
    Yun, Chae-Ok
    MOLECULAR THERAPY, 2011, 19 (08) : 1558 - 1568
  • [36] CXCR4 inhibition in combination with anti-PD1 immunotherapy results in an effective immune response during treatment with sorafenib in hepatocellular carcinoma
    Reiberger, Thomas
    Ramjiawan, Rakesh R.
    Chen, Yunching
    Ng, Mei R.
    Hato, Tai
    Unan, Elizabeth C.
    Reddy, Tejaswini P.
    Huang, Yuhui
    Ochiai, Hiroki
    Huang, Peigen
    Zhu, Andrew X.
    Jain, Rakesh K.
    Duda, Dan G.
    HEPATOLOGY, 2014, 60 : 644A - 644A
  • [37] Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1
    Naing, Aung
    Papadopoulos, Kyriakos P.
    Infante, Jeffrey R.
    Wong, Deborah Jean Lee
    Autio, Karen A.
    Ott, Patrick Alexander
    Falchook, Gerald Steven
    Patel, Manish R.
    Pant, Shubham
    Patnaik, Amita
    Mumm, John B.
    Whiteside, Melinda
    Chan, Ivan H.
    Bendell, Johanna C.
    Bauer, Todd Michael
    Janku, Filip
    Colen, Rivka R.
    Tannir, Nizar M.
    Van Vlasselaer, Peter
    Oft, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Anti-Tumor Effect of Tumor Specific Replicating Adenovirus Expressing IL-12 and IL-18
    Huang, Jing-Hua
    Choi, Il-Kyu
    Jung, Sung-Mi
    Kim, Minjung
    Sohn, Joo-Hyuk
    Yun, Chae-Ok
    Kim, Joo-Hang
    MOLECULAR THERAPY, 2006, 13 : S325 - S325
  • [39] Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
    Dearden, Helen
    Au, Lewis
    Wang, Daniel Y.
    Zimmer, Lisa
    Eroglu, Zeynep
    Smith, Jessica L.
    Cuvietto, Marcello
    Khoo, Chloe
    Atkinson, Victoria
    Lo, Serigne
    V. Long, Georgina
    Sandhu, Shahneen
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Johnson, Douglas B.
    Larkin, James
    Menzies, Alexander M.
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 168 - 178
  • [40] Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model
    Garofalo, Mariangela
    Bertinato, Laura
    Staniszewska, Monika
    Wieczorek, Magdalena
    Salmaso, Stefano
    Schrom, Silke
    Rinner, Beate
    Pancer, Katarzyna Wanda
    Kuryk, Lukasz
    PHARMACEUTICS, 2021, 13 (04)
12345